A. Beaulieu

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report

É. Turcotte, J. Beauregard, François-Alexandre Buteau, 2021, Frontiers in Endocrinology.

What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non–Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?

G. Turgeon, T. Akhurst, S. Siva, 2018, The Journal of Nuclear Medicine.

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

D. Murphy, T. Akhurst, B. Tran, 2019, The Journal of Nuclear Medicine.

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

J. Beauregard, M. Del Prete, François-Alexandre Buteau, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ( 177 Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer

D. Murphy, T. Akhurst, B. Tran, 2019 .

Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ( 177 Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer

D. Murphy, T. Akhurst, B. Tran, 2019 .